MA53831A - Méthodes permettant de réduire l'agrégation d'anticorps bispécifiques - Google Patents
Méthodes permettant de réduire l'agrégation d'anticorps bispécifiquesInfo
- Publication number
- MA53831A MA53831A MA053831A MA53831A MA53831A MA 53831 A MA53831 A MA 53831A MA 053831 A MA053831 A MA 053831A MA 53831 A MA53831 A MA 53831A MA 53831 A MA53831 A MA 53831A
- Authority
- MA
- Morocco
- Prior art keywords
- aggregation
- reducing
- methods
- specific antibodies
- antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862739542P | 2018-10-01 | 2018-10-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA53831A true MA53831A (fr) | 2022-01-05 |
Family
ID=70055398
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA053831A MA53831A (fr) | 2018-10-01 | 2019-09-27 | Méthodes permettant de réduire l'agrégation d'anticorps bispécifiques |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP3860567A4 (fr) |
JP (1) | JP2022512569A (fr) |
KR (1) | KR20210070314A (fr) |
CN (1) | CN112789028A (fr) |
AU (1) | AU2019351715A1 (fr) |
BR (1) | BR112021006220A2 (fr) |
CA (1) | CA3112655A1 (fr) |
CL (1) | CL2021000827A1 (fr) |
EA (1) | EA202190955A1 (fr) |
IL (1) | IL281621A (fr) |
MA (1) | MA53831A (fr) |
MX (1) | MX2021003628A (fr) |
SG (1) | SG11202102995PA (fr) |
WO (1) | WO2020072306A1 (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2021330845A1 (en) * | 2020-08-24 | 2023-01-19 | Amgen Inc. | Pharmaceutical formulation comprising a bite, bispecific antibody, and methionine |
WO2022060878A1 (fr) * | 2020-09-16 | 2022-03-24 | Amgen Inc. | Méthodes de traitement du cancer de la prostate |
MX2023003041A (es) * | 2020-09-16 | 2023-05-09 | Amgen Inc | Métodos para administrar dosis terapéuticas de moléculas de acoplamiento a células t biespecíficas para el tratamiento de cáncer. |
JP2024525482A (ja) * | 2021-06-30 | 2024-07-12 | アムジェン インコーポレイテッド | 凍結乾燥処方物を再構成する方法 |
WO2024059675A2 (fr) * | 2022-09-14 | 2024-03-21 | Amgen Inc. | Composition de stabilisation de molécule bispécifique |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104093744A (zh) * | 2011-10-11 | 2014-10-08 | 弗·哈夫曼-拉罗切有限公司 | 双特异性抗体的改进的组装 |
PL2916866T3 (pl) * | 2012-11-06 | 2018-10-31 | Bayer Pharma Aktiengesellschaft | Formulacja dwuswoistych przeciwciał mobilizujących limfocyty t (bite) |
TWI679019B (zh) * | 2013-04-29 | 2019-12-11 | 法商賽諾菲公司 | 抗il-4/抗il-13之雙特異性抗體調配物 |
MX2016014411A (es) * | 2014-05-07 | 2017-04-06 | Takeda Gmbh | Formulacion liquida que comprende un compuesto neutralizante de gm-csf. |
WO2016036678A1 (fr) * | 2014-09-02 | 2016-03-10 | Medimmune, Llc | Formulations d'anticorps bispécifiques |
BR112018014277A2 (pt) * | 2016-01-13 | 2018-12-18 | Genmab As | formulação, e, método de preparação de uma solução injetável de um axl-adc |
TWI797073B (zh) * | 2016-01-25 | 2023-04-01 | 德商安美基研究(慕尼黑)公司 | 包含雙特異性抗體建構物之醫藥組合物 |
TN2018000266A1 (en) * | 2016-02-03 | 2020-01-16 | Amgen Res Munich Gmbh | Psma and cd3 bispecific t cell engaging antibody constructs. |
BR112019022751A2 (pt) * | 2017-05-05 | 2020-05-19 | Amgen Inc | composição farmacêutica compreendendo construtos de anticorpos biespecíficos para armazenamento e administração melhorados |
EA202091422A1 (ru) * | 2017-12-11 | 2020-08-28 | Эмджен Инк. | Способ непрерывного производства продуктов на основе биспецифических антител |
-
2019
- 2019-09-27 CN CN201980064486.6A patent/CN112789028A/zh active Pending
- 2019-09-27 WO PCT/US2019/053462 patent/WO2020072306A1/fr unknown
- 2019-09-27 AU AU2019351715A patent/AU2019351715A1/en active Pending
- 2019-09-27 SG SG11202102995PA patent/SG11202102995PA/en unknown
- 2019-09-27 BR BR112021006220A patent/BR112021006220A2/pt unknown
- 2019-09-27 KR KR1020217012083A patent/KR20210070314A/ko unknown
- 2019-09-27 EA EA202190955A patent/EA202190955A1/ru unknown
- 2019-09-27 EP EP19869416.8A patent/EP3860567A4/fr active Pending
- 2019-09-27 MA MA053831A patent/MA53831A/fr unknown
- 2019-09-27 JP JP2021517615A patent/JP2022512569A/ja active Pending
- 2019-09-27 CA CA3112655A patent/CA3112655A1/fr active Pending
- 2019-09-27 MX MX2021003628A patent/MX2021003628A/es unknown
-
2021
- 2021-03-18 IL IL281621A patent/IL281621A/en unknown
- 2021-04-01 CL CL2021000827A patent/CL2021000827A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA3112655A1 (fr) | 2020-04-09 |
CL2021000827A1 (es) | 2021-10-15 |
EA202190955A1 (ru) | 2021-08-17 |
IL281621A (en) | 2021-05-31 |
WO2020072306A1 (fr) | 2020-04-09 |
SG11202102995PA (en) | 2021-04-29 |
EP3860567A4 (fr) | 2022-07-06 |
KR20210070314A (ko) | 2021-06-14 |
MX2021003628A (es) | 2021-05-27 |
EP3860567A1 (fr) | 2021-08-11 |
JP2022512569A (ja) | 2022-02-07 |
AU2019351715A1 (en) | 2021-04-22 |
BR112021006220A2 (pt) | 2021-07-06 |
CN112789028A (zh) | 2021-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA53831A (fr) | Méthodes permettant de réduire l'agrégation d'anticorps bispécifiques | |
MA46643A (fr) | Méthodes et compositions pour le mappage d'arn | |
MA53434A (fr) | Anticorps anti-tigit | |
MA50505A (fr) | Anticorps 2 + 1 bispécifiques (contorsbodies) | |
DK3625259T3 (da) | Anti-sirpalpha-antistoffer | |
MA52884A (fr) | Anticorps anti-il-11 | |
MA47694A (fr) | Anticorps anti-tigit | |
MA46057A (fr) | Anticorps anti-ctla4 | |
MA42925A (fr) | Anticorps anti-tigit et méthodes d'utilisation | |
MA47268A (fr) | Anticorps anti-gpc3 | |
MA55629A (fr) | Compositions d'anticorps pour le traitement de tumeurs | |
MA49726A (fr) | Formulation d'anticorps anti-cgrp | |
MA46315A (fr) | Polythérapies pour malignités hématologiques avec des anticorps anti-cd38 et des inhibiteurs de la survivine | |
MA50352A (fr) | Anticorps multispécifiques | |
MA46791A (fr) | Composés et procédés pour réduire l'expression d'atxn3 | |
MA43197A (fr) | Constructions d'anticorps bispécifiques pour cdh3 et cd3 | |
MA46963A (fr) | Méthodes pour déterminer le dosage de céllules car-t | |
IT201700070755A1 (it) | “sistema di separazione” | |
DK3606961T3 (da) | Garp-tgf-beta-antistoffer | |
MA44236A (fr) | Anticorps anti-tgfbêta 2 | |
MA52366A (fr) | Anticorps anti-tl1a optimisés | |
MA47494A (fr) | Nouvelles utilisations d'anticorps anti-sirpg | |
MA43378A (fr) | Compositions et méthodes pour la reduction de la réponse immunitaire contre récepteurs d'antigène chimériques | |
FR3022462B1 (fr) | Composition orale d'anticorps anti-tnfalpha | |
MA43416A (fr) | Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3 |